{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:34:28Z","timestamp":1770500068125,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1041,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p>\n                    <jats:bold>Study Objective.<\/jats:bold>\n                    To compare the effects of ropinirole with those of placebo on sleep, as evaluated by specific domains of the Medical Outcomes Study (MOS) sleep scale, as well as the Clinical Global Impression\u2010Improvement (CGI\u2010I) scale, in patients with restless legs syndrome (RLS).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design.<\/jats:bold>\n                    Meta\u2010analysis of six randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group trials conducted in the United States and Europe.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients.<\/jats:bold>\n                    A total of 1679 patients aged 18\u201379 years with primary moderate\u2010to\u2010severe RLS who received ropinirole (835 patients) or placebo (844 patients).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements and Main Results.<\/jats:bold>\n                    A systematic review of MEDLINE (January 1980\u2010January 2007) and clinical trial registers was performed to identify placebo\u2010controlled trials of ropinirole that used the 12\u2010item MOS sleep scale to assess sleep in patients with RLS. Individual patient data from both published and nonpublished trials were pooled for meta\u2010analysis. In the eligible studies, immediate\u2010release ropinirole 0.25\u20106 mg or placebo had been given for at least 12 weeks. In addition, sleep scale summary scores for the domains of sleep quantity, adequacy, disturbance, and daytime somnolence had to have been assessed at baseline and at 12 weeks. Our meta\u2010analysis found that at baseline study patients slept an average of 5.8 hours\/night. At the end of 12 weeks, ropinirole\u2010treated patients slept a mean of 2.5 hours\/week more and had a 21% greater improvement from baseline in sleep adequacy scores compared with patients receiving placebo. Ropinirole\u2010treated patients also had 14% less sleep disturbance and 8% less daytime somnolence than patients receiving placebo. Clinicians rated 63% of ropinirole\u2010treated patients and 47% of patients receiving placebo as responders based on the CGI\u2010I scale. Mixed effects analysis of covariance was used to estimate treatment effect adjusting for study center as a random effect, as well as the following fixed effects known to affect sleep: baseline sleep characteristics, age, sex, and chronic medical conditions. All differences were statistically significant (p&lt;0.05), even after adjusting for multiple comparisons.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    Pooled data from six similarly designed clinical trials provide evidence that ropinirole improves sleep quantity and adequacy, and lessens sleep disturbance and daytime somnolence in patients with primary RLS.\n                  <\/jats:p>","DOI":"10.1592\/phco.29.3.255","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T09:55:55Z","timestamp":1235728555000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Ropinirole on Sleep Outcomes in Patients with Restless Legs Syndrome: Meta\u2010Analysis of Pooled Individual Patient Data from Randomized Controlled Trials"],"prefix":"10.1002","volume":"29","author":[{"given":"Richard A.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charity G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia W.","family":"Gilsenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael O.","family":"Calloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2004.03.006"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.11.1286"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01862.x"},{"issue":"1","key":"e_1_2_1_5_2","first-page":"43","article-title":"Prevalence of restless leg syndrome (RLS) and impact of symptoms on the quality of life of sufferers","volume":"10","author":"Hening W","year":"2003","journal-title":"Eur J Neurol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1209"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4679(198901)45:1<51::AID-JCLP2270450107>3.0.CO;2-H"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01584.x-i1"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2006.01.001"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90136-1"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060031"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.916"},{"key":"e_1_2_1_13_2","first-page":"92","article-title":"Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries","volume":"75","author":"Trenkwalder C","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.5.907"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20257"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.1.17"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21050"},{"key":"e_1_2_1_18_2","article-title":"Psychometric evaluation and tests of validity of the medical outcomes study 12\u2010item sleep scale (MOS sleep) [published online ahead of print September 18, 2008]","author":"Allen RP","journal-title":"Sleep Med"},{"key":"e_1_2_1_19_2","first-page":"235","volume-title":"Measuring func tioning and well\u2010being: the medical outcomes study approach","author":"Hays RD","year":"1992"},{"key":"e_1_2_1_20_2","volume-title":"The clinician global severity and impression scales","author":"Guy W","year":"1976"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(02)00258-7"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/foc.3.4.568"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1647"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90034-6"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1191\/0962280205sm398oa"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2004.07.006"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-79"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/18.10.908"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:AHSE.0000038173.00909.f6"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93004-K"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(02)00443-9"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(02)00108-9"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.3.255","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.3.255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:45:26Z","timestamp":1761065126000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.3.255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1592\/phco.29.3.255"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.3.255","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}